Abstract
For most emerging infectious diseases, including SARS-Coronavirus-2 (SARS-CoV-2), pharmaceutical intervensions such as drugs and vaccines are not widely available, and disease surveillance followed by isolating, contact-tracing and quarantining infectious individuals is critical for controlling outbreaks. These interventions often begin by identifying symptomatic individuals. However, by actively removing pathogen strains likely to be symptomatic, such interventions may inadvertently select for strains less likely to result in symptomatic infections. Additionally, the pathogen’s fitness landscape is structured around a heterogeneous host pool. In particular, uneven surveillance efforts and distinct transmission risks across host classes can drastically alter selection pressures. Here we explore this interplay between evolution caused by disease control efforts, on the one hand, and host heterogeneity in the efficacy of public health interventions on the other, on the potential for a less symptomatic, but widespread, pathogen to evolve. We use an evolutionary epidemiology model parameterized for SARS-CoV-2, as the widespread potential for silent transmission by asymptomatic hosts has been hypothesized to account, in part, for its rapid global spread. We show that relying on symptoms-driven reporting for disease control ultimately shifts the pathogen’s fitness landscape and can cause pandemics. We find such outcomes result when isolation and quarantine efforts are intense, but insufficient for suppression. We further show that when host removal depends on the prevalence of symptomatic infections, intense isolation efforts can select for the emergence and extensive spread of more asymptomatic strains. The severity of selection pressure on pathogens caused by these interventions likely lies somewhere between the extremes of no intervention and thoroughly successful eradication. Identifying the levels of public health responses that facilitate selection for asymptomatic pathogen strains is therefore critical for calibrating disease suppression and surveillance efforts and for sustainably managing emerging infectious diseases.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors received no external funding for this project.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A as theoretical study
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
This is theoretical work so there is no data. Interested readers are invited to consult https://github.com/kewok/AsymptomaticEvolution for code used in the analyses